**Name of Journal: *World Journal of Hepatology***

**Manuscript NO: 48035**

**Manuscript Type: REVIEW**

**Cirrhotic patients and older people**

Carrier P *et al*. Cirrhotic patients

**Paul Carrier, Marilyne Debette-Gratien, Jérémie Jacques, Véronique Loustaud-Ratti**

**Paul Carrier, Marilyne Debette-Gratien, Véronique Loustaud-Ratti,** Fédération d’Hépatologie, Centre Hospitalier Universitaire Dupuytren de Limoges, Limoges 87042, France

**Paul Carrier, Marilyne Debette-Gratien, Véronique Loustaud-Ratti,** Faculté de Médecine et de Pharmacie de Limoges, Rue Docteur Marcland, Limoges 87042, France

**Jérémie Jacques,** Service de Gastroentérologie, Centre Hospitalier Universitaire Dupuytren de Limoges, Limoges 87042, France

**ORCID number:** Paul Carrier (0000-0001-9750-2506); Marilyne Debette-Gratien (0000-0001-6039-1355); Jérémie Jacques (0000-0003-4105-6804); Véronique Loustaud-Ratti (0000-0002-6951-0784).

**Author contributions:** Carrier P wrote the manuscript and oversaw editorial consistency; Debette-Gratien M and Jacques J reread the manuscript and assisted in the constitution of the bibliography; Loustaud-Ratti V reread the manuscript and oversaw editorial consistency.

**Conflict-of-interest statement:** The author declares no potential conflicts of interest in relation to this publication.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Véronique Loustaud-Ratti, MD, Professor,** Fédération d’Hépatologie, Centre Hospitalier Universitaire Dupuytren de Limoges, 2 Avenue Martin Luther King, Limoges 87042, France. veronique.loustaud-ratti@unilim.fr

**Telephone:** +33-5-5556684

**Received:** April 17, 2019

**Peer-review started:** April 17, 2019

**First decision:** June 3, 2019

**Revised:** June 18, 2019

**Accepted:** July 16, 2019

**Article in press:**

**Published online:**

**Abstract**

The global population is aging, and so the number of older cirrhotic patients is increasing. Older patients are characterised by a risk of frailty and comorbidities, and age is a risk factor for mortality in cirrhotic patients. The incidence of non-alcoholic fatty liver disease as an aetiology of cirrhosis is increasing, while that of chronic viral hepatitis is decreasing. Also, cirrhosis is frequently idiopathic. The management of portal hypertension in older cirrhotic patients is similar to that in younger patients, despite the greater risk of treatment-related adverse events of the former. The prevalence of hepatocellular carcinoma increases with age, but its treatment is unaffected. Liver transplantation is generally recommended for patients < 70 years of age. Despite the increasing prevalence of cirrhosis in older people, little data are available and few recommendations have been proposed. This review suggests that comorbidities have a considerable impact on older cirrhotic patients.

**Key words:** Liver cirrhosis; Portal hypertension; Liver cancer; Liver transplantation; Old age; Older; Elderly

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:**Few large studies have addressed the needs of older cirrhotic patients. The concept of healthy ageing is increasingly important. Cirrhosis is underdiagnosed in older patients, and comorbidities, comedications, and frailty impact the prognosis. The frequency of non-alcoholic fatty liver disease as an aetiology of cirrhosis is increasing, while that of viral hepatitis is decreasing, and the role of alcohol consumption is underestimated. The management of complications in older cirrhotic patients is similar to that in younger patients despite the higher risk of treatment-related adverse events. Therapeutic indications for a transjugular intrahepatic portosystemic shunt or admission to an intensive care unit should be carefully considered. Finally, older patients require tailored exercise and nutrition programs, and treatment of osteoporosis is crucial.

Carrier P, Debette-Gratien M, Jacques J, Loustaud-Ratti V. Cirrhotic patients and elderly. *World J Hepatol* 2019; In press

**INTRODUCTION**

The definition of older people varies from ≥ 60 years to ≥ 80 years of age. However, according to the World Health Organisation, the cut-off is 60 years of age, despite the increasing focus on the concept of healthy ageing[1,2]. Patients > 80 years of age are typically defined as being extremely old. Life expectancy has increased recently due to health, social, and economic development. According to the World Health Organisation, the number of people ≥ 65 years of age will increase from an estimated 524 million in 2010 to almost 1500 million in 2050, representing 22% of the global population[3]. Thus, the healthcare of older people is an emerging issue, particularly in Western countries.

The incidence of liver diseases increases with age[4]. Liver cirrhosis is an important health problem globally, and the prevalence of its numerous aetiologies varies geographically. General recommendations for the management of cirrhotic patients have been published, but these are not specific to older people[5].

This review focuses on problems specific to older cirrhotic patients.

**PATHOPHYSIOLOGY OF THE AGEING LIVER**

The liver undergoes physiological evolution with age, and this process involves several mechanisms. First, liver volume and blood flow decrease[6]. The liver decreases to one-third of its original size, more markedly in women[7], and a one-third decrease in hepatic blood flow has been reported, particularly in subjects over 75-years-old[8,9]. However, these results are controversial, and more data are needed[10]. Scintigraphy has shown that compared to the whole body, the size and functionality of the liver decrease with age[11]. Moreover, endothelial cell fenestration tends to decrease with age[8], the sinusoid vascular system is damaged, and secretion of bile acids is reduced. Regarding metabolic parameters, glucogenesis decreases with age but physiological lipids accumulate, enhancing steatosis[12]. Also, liver fat composition changes with age[13]; the level of high-density cholesterol and neutral fat is increased by neoglucogenesis. Moreover, older people tend to have higher levels of cholestatic enzymes and bilirubin[14].

Second, the number of hepatocytes and Kupffer cells and sinusoid capillaries decreases[8], and hepatocytes decrease in size with aging. The frequency of hepatocyte polyploidy increases with age and is associated with dysfunction or a decreased number of mitochondria[15]. Autophagy is modulated by accumulation of lipofuscin, a non-degradable aggregate of proteins impacted by reactive oxidative species[16]. Kupffer cells are also involved in ageing[17]. Cellular senescence is linked to chromosome alterations; telomere shortening occurs more frequently in Kupffer cells than in hepatocytes[18]. Apoptosis occurs more frequently in older patients, and senescent cells are resistant to apoptosis[19]. Nevertheless, targeting apoptosis of senescent cells could assist the restoration of liver homeostasis[20].

Third, the risk of fibrosis and steatosis increases with age[21]; for instance, in chronic hepatitis C virus (HCV) infection[22,23]. Fibrosis is a consequence of altered liver regeneration in response to injury. Responses to oxidative stress, cell senescence, and disrupted mitochondrial homeostasis may explain the greater risk of both fibrosis and steatosis in older patients[24]. In mouse models, mitochondria are damaged and the risk of DNA damage is increased by oxidative stress[12,25]. Altered liver regeneration may involve a multiprotein complex comprising CCAAT/enhancer binding protein α. Accumulation of this complex inhibits E2F-dependent promoters[26]. The somatotropic axis is also involved in liver regeneration[27]; however, a full mechanistic understanding remains elusive.

The immune system changes with age: regulatory T cells, peripheral B cells, monocytes/macrophages, and natural killer cells have reduced functionality, and dendritic cells have defective Ag presentation and T-cell activation[28,29]. The levels of markers of oxidation are not different between younger and older mice with CCl4 injury. However, the number of proinflammatory CD4+ cells, the expression level of T-helper type-2 cytokines by macrophages, and fibrogenesis are greater in older mice[30,31]. Furthermore, suppression of autophagy favours inflammation[32], and a high-fat diet increases the risk of liver fibrosis in older mice[33]. These factors also increase the risk of infection.

The role of ageing in carcinogenesis is debated—both protective and inductive mechanisms are reported[29,34,35]. The duration of exposure to carcinogens and a history of cirrhosis may promote hepatocellular carcinoma (HCC). Therefore, the aged liver is more sensitive to acute and chronic injury and is at greater risk of severe fibrosis or cirrhosis.

**EPIDEMIOLOGY**

Cirrhosis may be underdiagnosed in older persons, which is likely to be due to the presence of fewer clinical signs at presentation and less-frequent use of invasive diagnostic modalities[36,37].

Older patients with cirrhosis have a reduced life expectancy. Among 135 patients ≥ 80 years of age, Hoshida *et al*[38] showed that HCC, thrombocytopenia, and advanced fibrosis were associated with a low survival rate and that the alpha-fetoprotein and bilirubin levels were associated with hepatic carcinogenesis.

Older people also manifest deterioration in their general health[39], and cirrhosis may contribute to their frailty. Sarcopenia is frequent in older and in cirrhotic patients and contributes to the frailty of the former[33]. Specific policies to combat this are needed.

Finally, older patients have a higher incidence of complications, to which changes in the liver may contribute. Nevertheless, liver status does not impact the mortality rate of older patients. Therefore, effective screening methods and preventive measures are essential.

**AETIOLOGIES**

The risk of transmission of hepatitis B virus increases with age, and the prevalence varies geographically. Epidemiological studies in the United States reported a higher prevalence among patients > 50 years of age compared to those 20–49 and 6–19 years of age (1.5–2‑fold and 15–20-fold, respectively), irrespective of ethnicity[40]. Although vaccination policies have decreased the global prevalence of hepatitis V virus infection, there is no specific prevention strategy for older patients, in whom vaccination shows reduced efficacy[41].

In Western countries, the so-called baby-boomer generation is aging. The prevalence of HCV infection is high in this population: in the United States, > 75% of patients with HCV belong to this generation, and specific screening policies have been proposed[42]. HCV-related cirrhosis develops on average > 20 years after contact, which explains its incidence in this generation[43]. Nevertheless, the efficacy and tolerability of new direct anti-viral agents (DAA) is likely to decrease the prevalence of HCV infection in these geographical areas. However, many viraemic patients are unaware of their status, *e*.*g*., > 100,000 patients in France have not been diagnosed or treated[44–47]. In a large retrospective study conducted in 2006, *i*.*e*. prior to the DAA era, Thabut *et al*[23] showed that patients > 65 years of age had a high prevalence of chronic hepatitis C and 14% had liver cirrhosis; interestingly, patients > 80 years of age had a lower alanine transaminase level than those < 65 years of age. Interferon-based treatments are typically not tolerated by older patients, but new treatments are available. These have fewer side effects in polymedicated older patients, provided that the necessary precautions are taken, particularly in patients with a cardiac history and renal insufficiency, and that drug interactions are evaluated before starting treatment[48–50]. Older patients have been included in therapeutic studies[51]. The available treatments are effective in older patients, and no specific recommendations concern this population, including those with cirrhosis[50]. Decisions regarding the treatment of extremely old patients must take into account the benefit-risk ratio and the public-health perspective.

Metabolic syndrome is emerging globally, especially in Western countries, which have a higher prevalence of metabolic risk factors[52]. However, developing countries, including those in Asia and the Middle East, are also affected[53]. Metabolic syndrome is common in older people[54], who are at risk of evolution towards cirrhosis[55] and have an increasing prevalence of cirrhosis[56]. Furthermore, > 60-year-old patients with non-alcoholic fatty liver disease are more susceptible to HCC[52]. Treatment is non-specific and based on weight loss[57,58], although vitamin E reportedly impacts life expectancy[59]. However, use of vitamin E in older males is associated with an increased risk of prostate cancer[60].

The prevalence of cryptogenic cirrhosis is high in some countries. For instance, in India[61], patients tend to have or have had metabolic risk factors for cirrhosis, in agreement with Japanese data[62]. Also, older studies indicated an important role for hepatitis C[63].

Alcohol consumption is frequent and more deleterious in older persons[64,65]; indeed, its prevalence in the United States increased between 2001–2002 and 2012–2013[66]. The social problems faced by older persons, such as isolation, widowhood, and chronic illness, can promote alcohol consumption. Alcohol accumulation in the liver impacts survival in patients with liver disease, such as hepatitis C[67]. The prognosis is poor; half of cirrhotic patients die within 1 year of diagnosis[68,69]. Older patients are also impacted by a variety of other alcohol-related complications[70]. From a public-health perspective, alcohol consumption should be assessed using the Alcohol Use Disorder Identification Test-C questionnaire and hepatic risk by performing non-invasive tests for fibrosis[70]. Alcohol withdrawal should be managed by a healthcare professional specialised in addiction with an elder-specific focus[71,72]. Short- and intermediate-acting benzodiazepines are recommended for older patients with alcohol-withdrawal syndrome, particularly those with cirrhosis[73].

Autoimmune hepatitis is also frequent in older patients, especially post-menopausal females[74]. These individuals are more likely to have asymptomatic liver cirrhosis and HLA DR4. Treatment is based on corticosteroids and azathioprine, as in younger patients; however, the risk of relapse after steroid withdrawal is lower[74]. Nevertheless, in older patients with initial mild fibrosis, the benefit-risk ratio of steroid treatment must be discussed due to their lower risk of fibrosis progression and higher risk of side effects, notably osteoporosis, psychiatric conditions, and diabetes, compared to younger patients[75]. That is why budesonide or a minimal corticosteroid regimen is preferred[76]. Furthermore, older patients with autoimmune hepatitis should undergo regular evaluations of bone density.

Primary biliary cholangitis is frequent in older patients, particularly females[77]. Interestingly, ursodeoxycholic acid is more effective in older patients[78]. However, older patients were not specifically analysed in two recent phase-III studies of obeticholic acid and bezafibrate[79,80].

Primary sclerosing cholangitis (PSC) is generally diagnosed in the third to fourth decades of life, but a second peak around 70 years of age was noted in a Japanese population, with no mention of the fibrosis stage[81]. Eaton *et al*[82] indicated that older patients with PSC have a 10% risk of cirrhosis, similar to that in younger patients, but have a lower prevalence of small-duct PSC. Finally, hepatobiliary malignancy is more frequent in older patients. There are no specific recommendations concerning the treatment and management of complications, including the role of therapeutic endoscopy[83]. McGee *et al*[84] suggested a link between autoimmune liver disease and liver cancer, *i.e.* intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, and ampulla of Vater cancer, in older patients, particularly those with primary biliary cholangitis.

Other causes, such as alpha-1-anti-trypsin, Wilson disease, and haemochromatosis, particularly haemochromatosis of weak phenotypic penetrance, may be diagnosed late[69], especially in post-menopausal women. This means that complications, such as cirrhosis and HCC, are frequently present at the time of diagnosis[85,86]. Alpha-1-anti-trypsin deficiency is typically diagnosed at a late stage unless pulmonary symptoms are evident and early screening for liver disease is performed[87]. Wilson disease is frequently diagnosed early, although a few advanced cases have been reported[88,89].

**COMPLICATIONS OF CIRRHOSIS**

***HCC***

HCC is the fifth most prevalent cancer worldwide and the third most important cause of cancer-related mortality[90]. The incidence of HCC increases with age, and the prognosis is poor. However, aggressive treatment of HCC in older (including extremely old) patients with good liver function and a good performance status might improve the survival rate[91]. Indeed, in an Italian cohort, older patients with HCC had at the time of diagnosis a higher prevalence of comorbidities that negatively impacted the prognosis, a lower HCC stage, and better liver function than younger patients[92]. In another study, survival of elderly HCC patients was associated with liver damage and stage, but not age, with the exception of patients ≥ 80 years of age with a poor performance status[93].

Although HCC is more frequent in males, the proportion of females is higher among extremely old patients. The clinical presentation is typically weakness, nausea, and abdominal pain[69]. Ascites and hepatomegaly were frequent complications in a retrospective study[94]. Liver cirrhosis is a risk factor for HCC in younger and older patients, for whom the HCC screening recommendations are identical[95].

The therapeutic panel is the same in young and old patients, although decision-making is hampered by comorbidities, performance status, and life expectancy[92,96,97]. Specific age-linked scales have been developed[98]. The majority of the relevant studies were conducted in Asia. In large retrospective studies, surgery showed a trend towards an increase in the mortality rate with age[99–103]. Tumour size may not be a contraindication[104], and perioperative management and careful selection are needed[105]. Radiofrequency ablation can be effective against small tumours, *i.e.* radiofrequency ablation was more effective than hepatic resection in older patients with ≤ 3 cm HCC[106]. However, in another study, the global survival rate, but not the incidence of procedure-related adverse events, was comparable in older and younger patients[107]. Percutaneous injection of ethanol is effective against < 2 cm tumours[108].

The results of palliative transarterial chemoembolisation for older patients with advanced tumours are heterogeneous[96,109]. In a large retrospective trial, the overall survival rate of older patients was increased, but they were treated at an early stage[110]. Conversely, age over 60 years was independently associated with a poor prognosis. Interestingly, older patients were at greater risk of peptic ulcer (2.5% *vs* 0.5%)[111]. Although no data are available, radioembolisation is an interesting option for older patients with HCC[112] and is well tolerated by those with unresectable metastatic colon cancer[113].

Sorafenib is the most frequently prescribed chemotherapeutic. A French retrospective study showed that patients > 80 years of age had low tolerance of a fixed dose, and two thirds of them experienced grade IV adverse events[114]. Several Japanese studies have reported more hopeful results[115,116]. In one, a half dose of sorafenib was useful in the presence of adverse events and was better tolerated[116]. Age does not seem to influence the safety and efficacy of levantinib[117]. Phase III studies of Regorafenib and Ramucirumab have not specifically addressed older patients[118,119], but second-line cabozantinib increased the overall survival rate of patients > 65 years of age[120]. Unfortunately, data on immunotherapies, especially Nivolumab, are sparse.

***Portal hypertension***

Older people have a lower portal velocity and are not at increased risk of portal hypertension[121,122]. The treatment strategy is the same globally[5]. Beta‑blockers are permitted despite various contraindications, and complications, such as cardiovascular and pulmonary events and an increased frequency of hospital admission[123]. Hyponatremia, hypotension, and renal insufficiency are contraindications for use of beta-blockers in older patients, as in younger patients[124].

According to the REPOSI Italian register, liver cirrhosis is the major cause of variceal and non-variceal upper gastrointestinal bleeding in older patients[125].

Proton pump inhibitors are associated with an increased risk of infection and encephalopathy in cirrhotic patients, irrespective of age[126–128]. In older patients, the therapeutic recommendations must be respected to prevent inappropriate prescriptions.

There is no specific recommendation concerning ascites in older patients. Diuretics should be prescribed with caution because of an increased risk of complications, particularly hyponatremia[129]. Older patients are at greater risk of acute renal insufficiency, independently of the aetiology[130]. Age does not affect survival in patients with refractory ascites, although terlipressin may be associated with vascular complications[131]. Transjugular intrahepatic portosystemic shunt (TIPS) and liver transplantation are interesting therapeutic options but have limitations in older patients, as discussed below.

***Encephalopathy***

Encephalopathy is a life-threatening complication of cirrhosis to which older people are particularly susceptible[39], and it may be linked to an altered brain-gut axis[132]. Infection, myocardial infarction, and central nervous system injury can favour this complication[133]. Minimal hepatic encephalopathy is associated with falls[134]. Older patients, especially the most fragile, require supervision and care. Their treatment is not different from that of younger patients[135]. Preventative therapy is essential in cases of cirrhotic decompensation and constipation must be controlled.

**ACUTE ALCOHOLIC HEPATITIS**

Acute alcoholic hepatitis is linked to a history of alcohol consumption and typically occurs in patients around 50 years of age[136]; however, older patients predominate in nosocomial studies[136]. Age is predictive of survival and of the presence of liver cirrhosis and is included in the Age, Serum bilirubin, International Normalised Ratio, and Serum creatinine score and the Lille model[137,138]. Although older patients were not included in the largest therapeutic studies, it is a prognostic factor for survival post-treatment[139]. Prednisolone is the only validated medical treatment, but data on its efficacy in older patients are lacking. Furthermore, recent studies of liver transplantation did not include patients > 61 years of age[140].

**PULMONARY AND CARDIAC COMPLICATIONS**

The definition of hepatopulmonary syndrome differs according to age: an alveolar-arterial gradient of 15 and 20 mmHg in patients < 65 and ≥ 65 years of age, respectively[5,141]. Long-term oxygen therapy is recommended[5]. Liver transplantation is curative, and age does not influence the outcome of patients with hepatopulmonary syndrome[142].

Among other causes of pulmonary hypertension, cirrhosis is one of the most important in older people[143,144]. The presentation can differ with age; older patients are more likely to have oedema and a more severe presentation[145]. Their management does not differ from that of patients in other age groups, and the prognosis is similar[5,109].

Hydrothorax is also observed in older cirrhotic patients, and its management, despite the lack of data, is identical to that for younger patients. TIPS is a therapeutic solution, but, as in ascites, careful selection of patients is mandatory[146].

Old age is associated with an increased risk of cardiac dysfunction and cirrhotic cardiomyopathy[147]. Because of its frequency and prognostic impact, systematic screening for these conditions among older patients is justified[5].

**PATIENTS IN CRITICAL CONDITION**

The survival rate of cirrhotic patients in the intensive care unit is 34% to 69%[148]. Age > 75 years impacts the global, but not the intensive care unit, survival rate[149]. Although the severity of cirrhosis is more predictive of survival than age, age is an indication for admission to the intensive care unit[5]. Indeed, age is a parameter of the prognostic Chronic Liver Failure Consortium acute decompensation score and the Chronic Liver Failure Consortium acute on chronic liver failure score[150,151]. Hepatorenal syndrome and spontaneous bacterial peritonitis are associated with a poor prognosis[152].

**INFECTIONS**

Older cirrhotic patients are at increased risk of infection due to their impaired immunity defences[153]. Spontaneous bacterial peritonitis has a higher mortality rate in older than in younger people[154], and, although the data are sparse, older people are more susceptible to renal failure[155]. In cirrhotic patients, bacterial resistance to antibiotics is promoted by the high frequency of antibiotic use[156]. Age impacts the occurrence and mortality rate of infection with multiresistant bacteria, but not the risk of inappropriate treatment[157].

As mentioned above, the use of proton-pump inhibitors by older patients increases the risk of infection, and their use should be restricted. Of note, vitamin D deficiency, which is more frequent in older cirrhotic patients, is also a risk factor for infection[158]. Thus, screening for and correction of this deficiency is essential in older cirrhotic patients[159].

**SPECIFIC MANAGEMENT**

***Nutrition***

Although there are no specific recommendations for older cirrhotic patients, both age and cirrhosis are associated with frailty and malnutrition[160,161]. Sarcopenia is present in 1% to 29% of community-dwelling patients and in 14% to 33% of those in long-term care[160]. In older cirrhotic patients, assessment and correction of sarcopenia are crucial—computed tomography, measurement of the muscle area at L3, dual-energy X-ray absorptiometry, subjective global assessment, and Royal Free Hospital-Global assessment are useful in this regard[161]. Nutritional support can be helpful, particularly for critically ill patients. Exercise and physical activity tailored to the patient’s age and general condition are also required[58]. Furthermore, systematic screening for osteoporosis is advisable in cirrhotic patients and is vital in older cirrhotic patients.

***TIPS***

Age is a limiting factor for TIPS, independently of the model for end-stage liver disease (MELD) score[162,163]. This is why cardiac function (diastolic function, pulmonary arterial hypertension) and risk of encephalopathy of older patients must be evaluated. Altered cardiac pressure in the right atrium and in pulmonary vessels is associated with mortality[163]. Correction of the natriuresis balance in older patients is delayed after TIPS insertion[164]. Although they were not included in the largest study[5], recent retrospective data show that the procedure is beneficial in selected older patients[146].

**LIVER TRANSPLANTATION**

Durand *et al*[29] reviewed liver transplantation in older patients. In practice, liver transplantation is rarely possible in patients > 70 years of age. However, the proportion of patients > 65 years of age who are candidates for liver transplantation is increasing in the United States and in Europe[29,165]. Also, the epidemiology is changing: in the United States, the frequency of non‑alcoholic steatohepatitis and HCC as indications for liver transplantation is increasing, whereas that of HCV patients is decreasing[165]. The mortality rate among patients on the waiting list is higher in older people[165], as is the risk of dropping out; the mortality rate is higher in patients with a lower MELD score than in those < 64 years of age[165].

The 5-year post-transplantation mortality rate increases linearly with age in older recipients[166]. The MELD score is associated with mortality early post-liver transplantation[166], and older patients have a higher incidence of cardiac, pulmonary, and renal complications as well as of malignancies. Also, post-transplantation renal function is a key prognostic factor in patients transplanted for cirrhosis. Age impacts the occurrence of cirrhosis (relative risk per 10-year increment, 1.36; *P* < 0.001)[167] as does pre-transplantation acute renal insufficiency, especially when associated with hepatorenal syndrome. However, older patients are at greater risk of chronic renal insufficiency before liver transplantation[168]. So, selection of patients is crucial to prevent post-transplantation complications—such as cancer, metabolic disease, or renal insufficiency—and to improve overall survival. The recently developed Liver Frailty Index may be predictive of survival post-transplantation[169].

Notably, donor age impacts survival post liver transplantation. The impact of donor age begins at 40 years and increases with age, particularly at > 60 years of age[170]. Moreover, improvements in liver-graft selection have resulted in a 5-year post-transplantation survival rate of > 70%[171]. The Donor Risk Index includes the donor’s age, which is one of the three important risk factors for graft failure, in addition to donation after cardiac death and split/partial grafts[170]. Grafts with an increased Donor Risk Index are preferentially transplanted into older candidates > 50 years of age with moderate disease severity.

Finally, age matching, although complex, is warranted by a number of policies. A summed recipient and donor age of > 120 years may be prognostic, independently of other factors[172]. Other scores, such as the Survival Outcomes Following Liver Transplantation and Balance of Risk scores, include both donor and recipient factors[173,174].

In conclusion, few large studies have focused on older cirrhotic patients. The relevance of recent global recommendations on cirrhosis and transplantation is thus limited. In older patients, evaluation of comorbidities, comedications, and frailty is essential.

Relevant scores, such as the Frailty Liver Index, should be considered, and customised exercise and nutrition programs and osteoporosis therapy should be proposed to older cirrhotic patients. Moreover, attention should be paid to the choice of HCC treatment, the indications for TIPS insertion in patients with portal hypertension, and the indications for admission to the intensive care unit. Prevention policies are needed, because the causes of cirrhosis generally begin in the first decades of life. Finally, studies involving older cirrhotic patients, as well as specific recommendations, are needed.

**REFERENCES**

1 **World Health Organization**. Proposed working definition of an older person in Africa for the MDS Project [Internet]. WHO 2002 [cited 2019 Jan 29]. Available from: url: http://www.who.int/healthinfo/survey/ageingdefnolder/en/

2 **World Health Organization**. What is Healthy Ageing? [Internet]. WHO [cited 2019 Jan 29]. Available from: url: http://www.who.int/ageing/healthy-ageing/en/

3 **World Health Organization**. World Report on Ageing and Health [Internet]. WHO 2015 [cited 2019 Jan 29]. Available from: url: https://www.who.int/ageing/events/world-report-2015-launch/en/

4 **Sheedfar F**, Di Biase S, Koonen D, Vinciguerra M. Liver diseases and aging: friends or foes? *Aging Cell* 2013; **12**: 950-954 [PMID: 23815295 DOI: 10.1111/acel.12128]

5 **European Association for the Study of the Liver**; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. *J Hepatol* 2018; **69**: 406-460 [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024]

6 **Jansen PL**. Liver disease in the elderly. *Best Pract Res Clin Gastroenterol* 2002; **16**: 149-158 [PMID: 11977934 DOI: 10.1053/bega.2002.0271]

7 **Wynne HA**, Mutch E, James OF, Wright P, Rawlins MD, Woodhouse KW. The effect of age upon the affinity of microsomal mono-oxygenase enzymes for substrate in human liver. *Age Ageing* 1988; **17**: 401-405 [PMID: 3266441 DOI: 10.1093/ageing/17.6.401]

8 **Le Couteur DG**, Cogger VC, Markus AM, Harvey PJ, Yin ZL, Ansselin AD, McLean AJ. Pseudocapillarization and associated energy limitation in the aged rat liver. *Hepatology* 2001; **33**: 537-543 [PMID: 11230732 DOI: 10.1053/jhep.2001.22754]

9 **Zoli M**, Magalotti D, Bianchi G, Gueli C, Orlandini C, Grimaldi M, Marchesini G. Total and functional hepatic blood flow decrease in parallel with ageing. *Age Ageing* 1999; **28**: 29-33 [PMID: 10203201 DOI: 10.1093/ageing/28.1.29]

10 **Schmucker DL**. Aging and the liver: an update. *J Gerontol A Biol Sci Med Sci* 1998; **53**: B315-B320 [PMID: 9754128 DOI: 10.1093/gerona/53A.5.B315]

11 **Wakabayashi H**, Nishiyama Y, Ushiyama T, Maeba T, Maeta H. Evaluation of the effect of age on functioning hepatocyte mass and liver blood flow using liver scintigraphy in preoperative estimations for surgical patients: comparison with CT volumetry. *J Surg Res* 2002; **106**: 246-253 [PMID: 12175974 DOI: 10.1006/jsre.2002.6462]

12 **Petersen KF**, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. *Science* 2003; **300**: 1140-1142 [PMID: 12750520 DOI: 10.1126/science.1082889]

13 **Slawik M**, Vidal-Puig AJ. Lipotoxicity, overnutrition and energy metabolism in aging. *Ageing Res Rev* 2006; **5**: 144-164 [PMID: 16630750 DOI: 10.1016/j.arr.2006.03.004]

14 **Tietz NW**, Shuey DF, Wekstein DR. Laboratory values in fit aging individuals--sexagenarians through centenarians. *Clin Chem* 1992; **38**: 1167-1185 [PMID: 1596990]

15 **Schmucker DL**. Age-related changes in liver structure and function: Implications for disease? *Exp Gerontol* 2005; **40**: 650-659 [PMID: 16102930 DOI: 10.1016/j.exger.2005.06.009]

16 **Höhn A**, Grune T. Lipofuscin: formation, effects and role of macroautophagy. *Redox Biol* 2013; **1**: 140-144 [PMID: 24024146 DOI: 10.1016/j.redox.2013.01.006]

17 **Hilmer SN**, Cogger VC, Le Couteur DG. Basal activity of Kupffer cells increases with old age. *J Gerontol A Biol Sci Med Sci* 2007; **62**: 973-978 [PMID: 17895435 DOI: 10.1093/gerona/62.9.973]

18 **Verma S**, Tachtatzis P, Penrhyn-Lowe S, Scarpini C, Jurk D, Von Zglinicki T, Coleman N, Alexander GJ. Sustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver. *Hepatology* 2012; **56**: 1510-1520 [PMID: 22504828 DOI: 10.1002/hep.25787]

19 **Salminen A**, Ojala J, Kaarniranta K. Apoptosis and aging: increased resistance to apoptosis enhances the aging process. *Cell Mol Life Sci* 2011; **68**: 1021-1031 [PMID: 21116678 DOI: 10.1007/s00018-010-0597-y]

20 **Baar MP**, Brandt RMC, Putavet DA, Klein JDD, Derks KWJ, Bourgeois BRM, Stryeck S, Rijksen Y, van Willigenburg H, Feijtel DA, van der Pluijm I, Essers J, van Cappellen WA, van IJcken WF, Houtsmuller AB, Pothof J, de Bruin RWF, Madl T, Hoeijmakers JHJ, Campisi J, de Keizer PLJ. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. *Cell* 2017; **169**: 132-147.e16 [PMID: 28340339 DOI: 10.1016/j.cell.2017.02.031]

21 **Kim IH**, Kisseleva T, Brenner DA. Aging and liver disease. *Curr Opin Gastroenterol* 2015; **31**: 184-191 [PMID: 25850346 DOI: 10.1097/MOG.0000000000000176]

22 **Poynard T**, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. *J Hepatol* 2001; **34**: 730-739 [PMID: 11434620 DOI: 10.1016/S0168-8278(00)00097-0]

23 **Thabut D**, Le Calvez S, Thibault V, Massard J, Munteanu M, Di Martino V, Ratziu V, Poynard T. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? *Am J Gastroenterol* 2006; **101**: 1260-1267 [PMID: 16771947 DOI: 10.1111/j.1572-0241.2006.00556.x]

24 **Poulose N**, Raju R. Aging and injury: alterations in cellular energetics and organ function. *Aging Dis* 2014; **5**: 101-108 [PMID: 24729935 DOI: 10.14336/AD.2014.0500101]

25 **López-Diazguerrero NE**, Luna-López A, Gutiérrez-Ruiz MC, Zentella A, Königsberg M. Susceptibility of DNA to oxidative stressors in young and aging mice. *Life Sci* 2005; **77**: 2840-2854 [PMID: 15979101 DOI: 10.1016/j.lfs.2005.05.034]

26 **Timchenko NA**. Aging and liver regeneration. *Trends Endocrinol Metab* 2009; **20**: 171-176 [PMID: 19359195 DOI: 10.1016/j.tem.2009.01.005]

27 **Zerrad-Saadi A**, Lambert-Blot M, Mitchell C, Bretes H, Collin de l'Hortet A, Baud V, Chereau F, Sotiropoulos A, Kopchick JJ, Liao L, Xu J, Gilgenkrantz H, Guidotti JE. GH receptor plays a major role in liver regeneration through the control of EGFR and ERK1/2 activation. *Endocrinology* 2011; **152**: 2731-2741 [PMID: 21540290 DOI: 10.1210/en.2010-1193]

28 **Fulop T**, Larbi A, Kotb R, de Angelis F, Pawelec G. Aging, immunity, and cancer. *Discov Med* 2011; **11**: 537-550 [PMID: 21712020]

29 **Durand F**, Levitsky J, Cauchy F, Gilgenkrantz H, Soubrane O, Francoz C. Age and liver transplantation. *J Hepatol* 2019; **70**: 745-758 [PMID: 30576701 DOI: 10.1016/j.jhep.2018.12.009]

30 **Mahrouf-Yorgov M**, Collin de l'Hortet A, Cosson C, Slama A, Abdoun E, Guidotti JE, Fromenty B, Mitchell C, Gilgenkrantz H. Increased susceptibility to liver fibrosis with age is correlated with an altered inflammatory response. *Rejuvenation Res* 2011; **14**: 353-363 [PMID: 21548759 DOI: 10.1089/rej.2010.1146]

31 **Collins BH**, Holzknecht ZE, Lynn KA, Sempowski GD, Smith CC, Liu S, Parker W, Rockey DC. Association of age-dependent liver injury and fibrosis with immune cell populations. *Liver Int* 2013; **33**: 1175-1186 [PMID: 23710620 DOI: 10.1111/liv.12202]

32 **Ilyas G**, Zhao E, Liu K, Lin Y, Tesfa L, Tanaka KE, Czaja MJ. Macrophage autophagy limits acute toxic liver injury in mice through down regulation of interleukin-1β. *J Hepatol* 2016; **64**: 118-127 [PMID: 26325539 DOI: 10.1016/j.jhep.2015.08.019]

33 **Kim IH**, Xu J, Liu X, Koyama Y, Ma HY, Diggle K, You YH, Schilling JM, Jeste D, Sharma K, Brenner DA, Kisseleva T. Aging increases the susceptibility of hepatic inflammation, liver fibrosis and aging in response to high-fat diet in mice. *Age (Dordr)* 2016; **38**: 291-302 [PMID: 27578257 DOI: 10.1007/s11357-016-9938-6]

34 **Ruhland MK**, Loza AJ, Capietto AH, Luo X, Knolhoff BL, Flanagan KC, Belt BA, Alspach E, Leahy K, Luo J, Schaffer A, Edwards JR, Longmore G, Faccio R, DeNardo DG, Stewart SA. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. *Nat Commun* 2016; **7**: 11762 [PMID: 27272654 DOI: 10.1038/ncomms11762]

35 **Aravinthan AD**, Alexander GJM. Senescence in chronic liver disease: Is the future in aging? *J Hepatol* 2016; **65**: 825-834 [PMID: 27245432 DOI: 10.1016/j.jhep.2016.05.030]

36 **Fujimoto K**, Sawabe M, Sasaki M, Kino K, Arai T. Undiagnosed cirrhosis occurs frequently in the elderly and requires periodic follow ups and medical treatments. *Geriatr Gerontol Int* 2008; **8**: 198-203 [PMID: 18822004 DOI: 10.1111/j.1447-0594.2008.00470.x]

37 **Graudal N**, Leth P, Mårbjerg L, Galløe AM. Characteristics of cirrhosis undiagnosed during life: a comparative analysis of 73 undiagnosed cases and 149 diagnosed cases of cirrhosis, detected in 4929 consecutive autopsies. *J Intern Med* 1991; **230**: 165-171 [PMID: 1650808 DOI: 10.1111/j.1365-2796.1991.tb00425.x]

38 **Hoshida Y**, Ikeda K, Kobayashi M, Suzuki Y, Tsubota A, Saitoh S, Arase Y, Kobayashi M, Murashima N, Chayama K, Kumada H. Chronic liver disease in the extremely elderly of 80 years or more: clinical characteristics, prognosis and patient survival analysis. *J Hepatol* 1999; **31**: 860-866 [PMID: 10580583 DOI: 10.1016/S0168-8278(99)80287-6]

39 **Rakoski MO**, McCammon RJ, Piette JD, Iwashyna TJ, Marrero JA, Lok AS, Langa KM, Volk ML. Burden of cirrhosis on older Americans and their families: analysis of the health and retirement study. *Hepatology* 2012; **55**: 184-191 [PMID: 21858847 DOI: 10.1002/hep.24616]

40 **Wasley A**, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, Bell B. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. *J Infect Dis* 2010; **202**: 192-201 [PMID: 20533878 DOI: 10.1086/653622]

41 **Loustaud-Ratti V**, Jacques J, Debette-Gratien M, Carrier P. Hepatitis B and elders: An underestimated issue. *Hepatol Res* 2016; **46**: 22-28 [PMID: 25651806 DOI: 10.1111/hepr.12499]

42 **Zalesak M**, Francis K, Gedeon A, Gillis J, Hvidsten K, Kidder P, Li H, Martyn D, Orne L, Smith A, Kwong A. Current and future disease progression of the chronic HCV population in the United States. *PLoS One* 2013; **8**: e63959 [PMID: 23704962 DOI: 10.1371/journal.pone.0063959]

43 **D’Souza R**, Glynn MJ, Ushiro–Lumb I, Feakins R, Domizio P, Mears L, Alsced E, Kumar P, Sabin CA, Foster GR. Prevalence of Hepatitis C–Related Cirrhosis in Elderly Asian Patients Infected in Childhood. *Clinical Gastroenterol and Hepatol* 2005; **3**: 910–917 [DOI: 10.1016/S1542-3565(05)00527-6]

44 **Chhatwal J**, Wang X, Ayer T, Kabiri M, Chung RT, Hur C, Donohue JM, Roberts MS, Kanwal F. Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals. *Hepatology* 2016; **64**: 1442-1450 [PMID: 27015107 DOI: 10.1002/hep.28571]

45 **Zoulim F**, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. *Gut* 2015; **64**: 1824-1833 [PMID: 26449729 DOI: 10.1136/gutjnl-2015-310421]

46 **Deuffic-Burban S**, Deltenre P, Buti M, Stroffolini T, Parkes J, Mühlberger N, Siebert U, Moreno C, Hatzakis A, Rosenberg W, Zeuzem S, Mathurin P. Predicted effects of treatment for HCV infection vary among European countries. *Gastroenterology* 2012; **143**: 974-85.e14 [PMID: 22863764 DOI: 10.1053/j.gastro.2012.05.054]

47 **Loustaud-Ratti V**, Debette-Gratien M, Carrier P. European Association for the Study of the Liver and French hepatitis C recent guidelines: The paradigm shift. *World J Hepatol* 2018; **10**: 639-644 [PMID: 30386457 DOI: 10.4254/wjh.v10.i10.639]

48 **Rodríguez-Osorio I**, Cid P, Morano L, Castro Á, Suárez M, Delgado M, Margusino L, Meijide H, Pernas B, Tabernilla A, Pedreira JD, Mena Á, Poveda E. Real life experience with direct-acting antivirals agents against hepatitis C infection in elderly patients. *J Clin Virol* 2017; **88**: 58-61 [PMID: 28183063 DOI: 10.1016/j.jcv.2017.01.003]

49 **Fabrizio C**, Saracino A, Scudeller L, Milano E, Dell'Acqua R, Bruno G, Lo Caputo S, Monno L, Milella M, Angarano G. The elderly and direct antiviral agents: Constraint or challenge? *Dig Liver Dis* 2017; **49**: 1036-1042 [PMID: 28651903 DOI: 10.1016/j.dld.2017.05.019]

50 **European Association for the Study of the Liver**. EASL Recommendations on Treatment of Hepatitis C 2016. *J Hepatol* 2017; **66**: 153-194 [PMID: 27667367 DOI: 10.1016/j.jhep.2016.09.001]

51 **Poordad F**, Nelson DR, Feld JJ, Fried MW, Wedemeyer H, Larsen L, Cohen DE, Cohen E, Mobashery N, Tatsch F, Foster GR. Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. *J Hepatol* 2017; **67**: 700-707 [PMID: 28645740 DOI: 10.1016/j.jhep.2017.06.011]

52 **Frith J**, Day CP, Henderson E, Burt AD, Newton JL. Non-alcoholic fatty liver disease in older people. *Gerontology* 2009; **55**: 607-613 [PMID: 19690397 DOI: 10.1159/000235677]

53 **Younossi Z**, Tacke F, Arrese M, Chander Sharma B, Mostafa I, Bugianesi E, Wai-Sun Wong V, Yilmaz Y, George J, Fan J, Vos MB. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. *Hepatology* 2019; **69**: 2672-2682 [PMID: 30179269 DOI: 10.1002/hep.30251]

54 **Bertolotti M**, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, Romagnoli D, Loria P. Nonalcoholic fatty liver disease and aging: epidemiology to management. *World J Gastroenterol* 2014; **20**: 14185-14204 [PMID: 25339806 DOI: 10.3748/wjg.v20.i39.14185]

55 **Angulo P**, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. *Hepatology* 1999; **30**: 1356-1362 [PMID: 10573511 DOI: 10.1002/hep.510300604]

56 **Estes C**, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. *Hepatology* 2018; **67**: 123-133 [PMID: 28802062 DOI: 10.1002/hep.29466]

57 AASLD. NAFLD Guidance 2018. [cited 2019 Feb 24]; Available from: https://www.aasld.org/sites/default/files/NAFLD%20Guidance%202018.pdf

58 **European Association for the Study of the Liver (EASL)**; European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol* 2016; **64**: 1388-1402 [PMID: 27062661 DOI: 10.1016/j.jhep.2015.11.004]

59 **Vilar-Gomez E**, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, Chalasani N. Vitamin E Improves Transplant-Free Survival and Hepatic Decompensation Among Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis. *Hepatology* 2018 [PMID: 30506586 DOI: 10.1002/hep.30368]

60 **Klein EA**, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Klotz L, Parsons JK, Chin JL, Darke AK, Lippman SM, Goodman GE, Meyskens FL Jr, Baker LH. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *JAMA* 2011; **306**: 1549-1556 [PMID: 21990298 DOI: 10.1001/jama.2011.1437]

61 **Goel A**, Madhu K, Zachariah U, Sajith KG, Ramachandran J, Ramakrishna B, Gibikote S, Jude J, Chandy GM, Elias E, Eapen CE. A study of aetiology of portal hypertension in adults (including the elderly) at a tertiary centre in southern India. *Indian J Med Res* 2013; **137**: 922-927 [PMID: 23760378]

62 **Tsutsui H**, Aramaki T, Okumura H. [Etiologic and pathophysiological characteristics of cirrhosis of the elderly]. *Nihon Ika Daigaku Zasshi* 1991; **58**: 507-517 [PMID: 1660492 DOI: 10.1272/jnms1923.58.507]

63 **Sugimura T**, Sakai H, Nawata H, Sakamoto M, Akazawa K, Nose Y. Etiology and prognosis of liver cirrhosis in elderly patients. *Fukuoka Igaku Zasshi* 1995; **86**: 411-416 [PMID: 8566928]

64 **Forrest EH**, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, Fisher NC, Singhal S, Brind A, Haydon G, O'Grady J, Day CP, Hayes PC, Murray LS, Morris AJ. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. *Gut* 2005; **54**: 1174-1179 [PMID: 16009691 DOI: 10.1136/gut.2004.050781]

65 **Wadd S**, Galvani S. Working with Older People with Alcohol Problems: Insight from Specialist Substance Misuse Professionals and their Service Users. *Soc Work Edu* 2014; **33**: 656–669 [DOI: 10.1080/02615479.2014.919076]

66 **Grant BF**, Chou SP, Saha TD, Pickering RP, Kerridge BT, Ruan WJ, Huang B, Jung J, Zhang H, Fan A, Hasin DS. Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV Alcohol Use Disorder in the United States, 2001-2002 to 2012-2013: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. *JAMA Psychiatry* 2017; **74**: 911-923 [PMID: 28793133 DOI: 10.1001/jamapsychiatry.2017.2161]

67 **Monto A**, Patel K, Bostrom A, Pianko S, Pockros P, McHutchison JG, Wright TL. Risks of a range of alcohol intake on hepatitis C-related fibrosis. *Hepatology* 2004; **39**: 826-834 [PMID: 14999703 DOI: 10.1002/hep.20127]

68 **Smith JW**. Medical manifestations of alcoholism in the elderly. *Int J Addict* 1995; **30**: 1749-1798 [PMID: 8751318 DOI: 10.3109/10826089509071055]

69 **Frith J**, Jones D, Newton JL. Chronic liver disease in an ageing population. *Age Ageing* 2009; **38**: 11-18 [PMID: 19029099 DOI: 10.1093/ageing/afn242]

70 **Hydes T**, Gilmore W, Sheron N, Gilmore I. Treating alcohol-related liver disease from a public health perspective. *J Hepatol* 2019; **70**: 223-236 [PMID: 30658724 DOI: 10.1016/j.jhep.2018.10.036]

71 **Rigler SK**. Alcoholism in the elderly. *Am Fam Physician* 2000; **61**: 1710-1716, 1883-1884, 1887-8 passim [PMID: 10750878]

72 **Armstrong-Moore R**, Haighton C, Davinson N, Ling J. Interventions to reduce the negative effects of alcohol consumption in older adults: a systematic review. *BMC Public Health* 2018; **18**: 302 [PMID: 29490636 DOI: 10.1186/s12889-018-5199-x]

73 **McKeon A**, Frye MA, Delanty N. The alcohol withdrawal syndrome. *J Neurol Neurosurg Psychiatry* 2008; **79**: 854-862 [PMID: 17986499 DOI: 10.1136/jnnp.2007.128322]

74 **Chen J**, Eslick GD, Weltman M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. *Aliment Pharmacol Ther* 2014; **39**: 117-124 [PMID: 24261965 DOI: 10.1111/apt.12563]

75 **European Association for the Study of the Liver**. EASL Clinical Practice Guidelines: Autoimmune hepatitis*. J Hepatol* 2015; **63**: 971-1004 [PMID: 26341719 DOI: 10.1016/j.jhep.2015.06.030]

76 **Rizvi S**, Gawrieh S. Autoimmune Hepatitis in the Elderly: Diagnosis and Pharmacologic Management. *Drugs Aging* 2018; **35**: 589-602 [PMID: 29971609 DOI: 10.1007/s40266-018-0556-0]

77 **Boonstra K**, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. *J Hepatol* 2012; **56**: 1181-1188 [PMID: 22245904 DOI: 10.1016/j.jhep.2011.10.025]

78 **Cheung AC**, Lammers WJ, Murillo Perez CF, van Buuren HR, Gulamhusein A, Trivedi PJ, Lazaridis KN, Ponsioen CY, Floreani A, Hirschfield GM, Corpechot C, Mayo MJ, Invernizzi P, Battezzati PM, Parés A, Nevens F, Thorburn D, Mason AL, Carbone M, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Verhelst X, Lindor KD, Lleo A, Poupon R, Janssen HL, Hansen BE; Global PBC Study Group. Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. *Clin Gastroenterol Hepatol* 2019 [PMID: 30616022 DOI: 10.1016/j.cgh.2018.12.028]

79 **Corpechot C**, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R. A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. *N Engl J Med* 2018; **378**: 2171-2181 [PMID: 29874528 DOI: 10.1056/NEJMoa1714519]

80 **Nevens F**, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. *N Engl J Med* 2016; **375**: 631-643 [PMID: 27532829 DOI: 10.1056/NEJMoa1509840]

81 **Takikawa H**. Characteristics of primary sclerosing cholangitis in Japan. *Hepatol Res* 2007; **37 Suppl 3**: S470-S473 [PMID: 17931205 DOI: 10.1111/j.1872-034X.2007.00241.x]

82 **Eaton JE**, McCauley BM, Atkinson EJ, Juran BD, Schlicht EM, de Andrade M, Lazaridis KN. Variations in primary sclerosing cholangitis across the age spectrum. *J Gastroenterol Hepatol* 2017; **32**: 1763-1768 [PMID: 28245345 DOI: 10.1111/jgh.13774]

83 **Sirpal S**, Chandok N. Primary sclerosing cholangitis: diagnostic and management challenges. *Clin Exp Gastroenterol* 2017; **10**: 265-273 [PMID: 29138587 DOI: 10.2147/CEG.S105872]

84 **McGee EE**, Castro FA, Engels EA, Freedman ND, Pfeiffer RM, Nogueira L, Stolzenberg-Solomon R, McGlynn KA, Hemminki K, Koshiol J. Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. *Int J Cancer* 2019; **144**: 707-717 [PMID: 30155920 DOI: 10.1002/ijc.31835]

85 **Bardou-Jacquet E**, Morcet J, Manet G, Lainé F, Perrin M, Jouanolle AM, Guyader D, Moirand R, Viel JF, Deugnier Y. Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. *J Hepatol* 2015; **62**: 682-689 [PMID: 25450707 DOI: 10.1016/j.jhep.2014.10.025]

86 **Nowak A**, Giger RS, Krayenbuehl PA. Higher age at diagnosis of hemochromatosis is the strongest predictor of the occurrence of hepatocellular carcinoma in the Swiss hemochromatosis cohort: A prospective longitudinal observational study. *Medicine* (Baltimore) 2018; **97**: e12886 [PMID: 30335010 DOI: 10.1097/MD.0000000000012886]

87 **Roggli VL**, Hausner RJ, Askew JB Jr. Alpha-1-antitrypsin globules in hepatocytes of elderly persons with liver disease. *Am J Clin Pathol* 1981; **75**: 538-542 [PMID: 7013469 DOI: /10.1093/ajcp/75.4.538]

88 **Kumagi T**, Horiike N, Michitaka K, Hasebe A, Kawai K, Tokumoto Y, Nakanishi S, Furukawa S, Hiasa Y, Matsui H, Kurose K, Matsuura B, Onji M. Recent clinical features of Wilson's disease with hepatic presentation. *J Gastroenterol* 2004; **39**: 1165-1169 [PMID: 15622480 DOI: 10.1007/s00535-004-1466-y]

89 **Poujois A**, Woimant F. Wilson's disease: A 2017 update. *Clin Res Hepatol Gastroenterol* 2018; **42**: 512-520 [PMID: 29625923 DOI: 10.1016/j.clinre.2018.03.007]

90 **El-Serag HB**, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. *Gastroenterology* 2007; **132**: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061]

91 **Tsukioka G**, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H, Abe T, Toyoda M, Katakai K, Kojima A, Yamazaki Y, Otsuka T, Matsuzaki Y, Makita F, Kanda D, Horiuchi K, Hamada T, Kaneko M, Suzuki H, Mori M. Hepatocellular carcinoma in extremely elderly patients: an analysis of clinical characteristics, prognosis and patient survival. *World J Gastroenterol* 2006; **12**: 48-53 [PMID: 16440416 DOI: 10.3748/wjg.v12.i1.48]

92 **Mirici-Cappa F**, Gramenzi A, Santi V, Zambruni A, Di Micoli A, Frigerio M, Maraldi F, Di Nolfo MA, Del Poggio P, Benvegnù L, Rapaccini G, Farinati F, Zoli M, Borzio F, Giannini EG, Caturelli E, Bernardi M, Trevisani F; Italian Liver Cancer Group. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. *Gut* 2010; **59**: 387-396 [PMID: 20207642 DOI: 10.1136/gut.2009.194217]

93 **Fujii H**, Itoh Y, Ohnishi N, Sakamoto M, Ohkawara T, Sawa Y, Nishida K, Ohkawara Y, Yamaguchi K, Minami M, Okanoue T. Factors associated with the overall survival of elderly patients with hepatocellular carcinoma. *World J Gastroenterol* 2012; **18**: 1926-1932 [PMID: 22563173 DOI: 10.3748/wjg.v18.i16.1926]

94 **Collier JD**, Curless R, Bassendine MF, James OF. Clinical features and prognosis of hepatocellular carcinoma in Britain in relation to age. *Age Ageing* 1994; **23**: 22-27 [PMID: 8010166 DOI: 10.1093/ageing/23.1.22]

95 **Trevisani F**, Cantarini MC, Labate AM, De Notariis S, Rapaccini G, Farinati F, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M; Italian Liver Cancer (ITALICA) group. Surveillance for hepatocellular carcinoma in elderly Italian patients with cirrhosis: effects on cancer staging and patient survival. *Am J Gastroenterol* 2004; **99**: 1470-1476 [PMID: 15307862 DOI: 10.1111/j.1572-0241.2004.30137.x]

96 **Poon RT**, Fan ST, Lo CM, Liu CL, Ngan H, Ng IO, Wong J. Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management. *Am J Gastroenterol* 1999; **94**: 2460-2466 [PMID: 10484009 DOI: 10.1111/j.1572-0241.1999.01376.x]

97 **Wang TE**, Chang CW, Liu CY, Chen MJ, Chu CH, Lin SC, Wang HY. Clinical Characteristics of Hepatocellular Carcinoma in Elderly Patients. *Inter J Gerontol* 2013; **7**: 85–89 [DOI: 10.1016/j.ijge.2013.03.003]

98 **Boulahssass R**, Gonfrier S, Champigny N, Lassalle S, François E, Hofman P, Guerin O. The Desire to Better Understand Older Adults with Solid Tumors to Improve Management: Assessment and Guided Interventions-The French PACA EST Cohort Experience. *Cancers* (Basel) 2019; **11** [PMID: 30736406 DOI: 10.3390/cancers11020192]

99 . Yanaga K, Kanematsu T, Takenaka K, Matsumata T, Yoshida Y, Sugimachi K. Hepatic resection for hepatocellular carcinoma in elderly patients. *Am J Surg* 1988; **155**: 238–241 [DOI: 10.1016/S0002-9610(88)80703-7]

100 **Nozawa A**, Kubo S, Takemura S, Sakata C, Urata Y, Nishioka T, Kinoshita M, Hamano G, Uenishi T, Suehiro S. Hepatic resection for hepatocellular carcinoma in super-elderly patients aged 80 years and older in the first decade of the 21st century. *Surg Today* 2015; **45**: 851-857 [PMID: 25113072 DOI: 10.1007/s00595-014-0994-1]

101 **Lee CR**, Lim JH, Kim SH, Ahn SH, Park YN, Choi GH, Choi JS, Kim KS. A comparative analysis of hepatocellular carcinoma after hepatic resection in young versus elderly patients. *J Gastrointest Surg* 2012; **16**: 1736-1743 [PMID: 22810298 DOI: 10.1007/s11605-012-1966-7]

102 **Kondo K**, Chijiiwa K, Funagayama M, Kai M, Otani K, Ohuchida J. Hepatic resection is justified for elderly patients with hepatocellular carcinoma. *World J Surg* 2008; **32**: 2223-2229 [PMID: 18642042 DOI: 10.1007/s00268-008-9688-4]

103 **Yeh CN**, Lee WC, Jeng LB, Chen MF. Hepatic resection for hepatocellular carcinoma in elderly patients. *Hepatogastroenterology* 2004; **51**: 219-223 [PMID: 15011868]

104 **Ferrero A**, Viganò L, Polastri R, Ribero D, Lo Tesoriere R, Muratore A, Capussotti L. Hepatectomy as treatment of choice for hepatocellular carcinoma in elderly cirrhotic patients. *World J Surg* 2005; **29**: 1101-1105 [PMID: 16088422 DOI: 10.1007/s00268-005-7768-2]

105 **Inoue Y**, Tanaka R, Fujii K, Kawaguchi N, Ishii M, Masubuchi S, Yamamoto M, Hirokawa F, Hayashi M, Uchiyama K. Surgical Outcome and Hepatic Regeneration after Hepatic Resection for Hepatocellular Carcinoma in Elderly Patients. *Dig Surg* 2019; **36**: 289-301 [PMID: 29758561 DOI: 10.1159/000488327]

106 **Peng ZW**, Liu FR, Ye S, Xu L, Zhang YJ, Liang HH, Lin XJ, Lau WY, Chen MS. Radiofrequency ablation versus open hepatic resection for elderly patients (&gt; 65 years) with very early or early hepatocellular carcinoma. *Cancer* 2013; **119**: 3812-3820 [PMID: 23922119 DOI: 10.1002/cncr.28293]

107 **Nishikawa H**, Osaki Y, Iguchi E, Takeda H, Ohara Y, Sakamoto A, Hatamaru K, Henmi S, Saito S, Nasu A, Kita R, Kimura T. Percutaneous radiofrequency ablation for hepatocellular carcinoma: clinical outcome and safety in elderly patients. *J Gastrointestin Liver Dis* 2012; **21**: 397-405 [PMID: 23256123]

108 **Teratani T**, Ishikawa T, Shiratori Y, Shiina S, Yoshida H, Imamura M, Obi S, Sato S, Hamamura K, Omata M. Hepatocellular carcinoma in elderly patients: beneficial therapeutic efficacy using percutaneous ethanol injection therapy. *Cancer* 2002; **95**: 816-823 [PMID: 12209726 DOI: 10.1002/cncr.10735]

109 **Sithamparanathan S**, Nair A, Thirugnanasothy L, Coghlan JG, Condliffe R, Dimopoulos K, Elliot CA, Fisher AJ, Gaine S, Gibbs JSR, Gatzoulis MA, E Handler C, Howard LS, Johnson M, Kiely DG, Lordan JL, Peacock AJ, Pepke-Zaba J, Schreiber BE, Sheares KKK, Wort SJ, Corris PA; National Pulmonary Hypertension Service Research Collaboration of the United Kingdom and Ireland. Survival in portopulmonary hypertension: Outcomes of the United Kingdom National Pulmonary Arterial Hypertension Registry. *J Heart Lung Transplant* 2017; **36**: 770-779 [PMID: 28190786 DOI: 10.1016/j.healun.2016.12.014]

110 **Mondazzi L**, Bottelli R, Brambilla G, Rampoldi A, Rezakovic I, Zavaglia C, Alberti A, Idèo G. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. *Hepatology* 1994; **19**: 1115-1123 [PMID: 7513677 DOI: 10.1002/hep.1840190508]

111 **Yau T**, Yao TJ, Chan P, Epstein RJ, Ng KK, Chok SH, Cheung TT, Fan ST, Poon RT. The outcomes of elderly patients with hepatocellular carcinoma treated with transarterial chemoembolization. *Cancer* 2009; **115**: 5507-5515 [PMID: 19701904 DOI: 10.1002/cncr.24636]

112 **Salem R**, Gordon AC, Mouli S, Hickey R, Kallini J, Gabr A, Mulcahy MF, Baker T, Abecassis M, Miller FH, Yaghmai V, Sato K, Desai K, Thornburg B, Benson AB, Rademaker A, Ganger D, Kulik L, Lewandowski RJ. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. *Gastroenterology* 2016; **151**: 1155-1163.e2 [PMID: 27575820 DOI: 10.1053/j.gastro.2016.08.029]

113 **Kennedy AS**, Ball DS, Cohen SJ, Cohn M, Coldwell D, Drooz A, Ehrenwald E, Kanani S, Rose SC, Nutting CW, Moeslein FM, Savin MA, Schirm S, Putnam SG 3rd, Sharma NK, Wang EA; Metastatic Colorectal Cancer Liver Metastases Outcomes After Radioembolization (MORE) Study Investigators. Safety and Efficacy of Radioembolization in Elderly (≥ 70 Years) and Younger Patients With Unresectable Liver-Dominant Colorectal Cancer. *Clin Colorectal Cancer* 2016; **15**: 141-151.e6 [PMID: 26541321 DOI: 10.1016/j.clcc.2015.09.001]

114 **Williet N**, Clavel L, Bourmaud A, Verot C, Bouarioua N, Roblin X, Merle P, Phelip JM. Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma. *Dig Liver Dis* 2017; **49**: 1043-1049 [PMID: 28712860 DOI: 10.1016/j.dld.2017.06.008]

115 **Jo M**, Yasui K, Kirishima T, Shima T, Niimi T, Katayama T, Mori T, Funaki J, Sumida Y, Fujii H, Takami S, Kimura H, Mitsumoto Y, Minami M, Yamaguchi K, Yoshinami N, Mizuno M, Sendo R, Tanaka S, Shintani H, Kagawa K, Okanoue T, Itoh Y. Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma. *Hepatol Res* 2014; **44**: 1329-1338 [PMID: 24528772 DOI: 10.1111/hepr.12308]

116 **Morimoto M**, Numata K, Kondo M, Kobayashi S, Ohkawa S, Hidaka H, Nakazawa T, Okuwaki Y, Okuse C, Matsunaga K, Suzuki M, Morita S, Taguri M, Tanaka K. Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis. *Hepatol Res* 2015; **45**: 279-287 [PMID: 24802232 DOI: 10.1111/hepr.12354]

117 **Hiraoka A**, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Shibata H, Ishikawa T, Ochi H, Tada T, Toyoda H, Nouso K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis. *Cancer Med* 2019; **8**: 137-146 [PMID: 30575325 DOI: 10.1002/cam4.1909]

118 **Bruix J**, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017; **389**: 56-66 [PMID: 27932229 DOI: 10.1016/S0140-6736(16)32453-9]

119 **Zhu AX**, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; **20**: 282-296 [PMID: 30665869 DOI: 10.1016/S1470-2045(18)30937-9]

120 **Abou-Alfa GK**, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klümpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. *N Engl J Med* 2018; **379**: 54-63 [PMID: 29972759 DOI: 10.1056/NEJMoa1717002]

121 **Antler AS**, Pitchumoni CS, Thomas E, Orangio G, Scanlan BC. Gastrointestinal bleeding in the elderly. Morbidity, mortality and cause. *Am J Surg* 1981; **142**: 271-273 [PMID: 6973291 DOI: 10.1016/0002-9610(81)90291-9]

122 **Zoli M**, Iervese T, Abbati S, Bianchi GP, Marchesini G, Pisi E. Portal blood velocity and flow in aging man. *Gerontology* 1989; **35**: 61-65 [PMID: 2792785 DOI: 10.1159/000213000]

123 **Oscanoa TJ**, Lizaraso F, Carvajal A. Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. *Eur J Clin Pharmacol* 2017; **73**: 759-770 [PMID: 28251277 DOI: 10.1007/s00228-017-2225-3]

124 **de Franchis R**; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. *J Hepatol* 2015; **63**: 743-752 [PMID: 26047908 DOI: 10.1016/j.jhep.2015.05.022]

125 **Lenti MV**, Pasina L, Cococcia S, Cortesi L, Miceli E, Caccia Dominioni C, Pisati M, Mengoli C, Perticone F, Nobili A, Di Sabatino A, Corazza GR; REPOSI Investigators. Mortality rate and risk factors for gastrointestinal bleeding in elderly patients. *Eur J Intern Med* 2019; **61**: 54-61 [PMID: 30522789 DOI: 10.1016/j.ejim.2018.11.003]

126 **Bajaj JS**, Ratliff SM, Heuman DM, Lapane KL. Proton pump inhibitors are associated with a high rate of serious infections in veterans with decompensated cirrhosis. *Aliment Pharmacol Ther* 2012; **36**: 866-874 [PMID: 22966967 DOI: 10.1111/apt.12045]

127 **Freedberg DE**, Kim LS, Yang YX. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. *Gastroenterology* 2017; **152**: 706-715 [PMID: 28257716 DOI: 10.1053/j.gastro.2017.01.031]

128 **Tsai CF**, Chen MH, Wang YP, Chu CJ, Huang YH, Lin HC, Hou MC, Lee FY, Su TP, Lu CL. Proton Pump Inhibitors Increase Risk for Hepatic Encephalopathy in Patients With Cirrhosis in A Population Study. *Gastroenterology* 2017; **152**: 134-141 [PMID: 27639806 DOI: 10.1053/j.gastro.2016.09.007]

129 **Sharabi Y**, Illan R, Kamari Y, Cohen H, Nadler M, Messerli FH, Grossman E. Diuretic induced hyponatraemia in elderly hypertensive women. *J Hum Hypertens* 2002; **16**: 631-635 [PMID: 12214259 DOI: 10.1038/sj.jhh.1001458]

130 **Heidemann J**, Bartels C, Berssenbrügge C, Schmidt H, Meister T. Hepatorenal syndrome: outcome of response to therapy and predictors of survival. *Gastroenterol Res Pract* 2015; **2015**: 457613 [PMID: 25983746 DOI: 10.1155/2015/457613]

131 **Cavallin M**, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, Gola E, Morando F, Stanco M, Rosi S, Sticca A, Cillo U, Angeli P. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study. *Hepatology* 2016; **63**: 983-992 [PMID: 26659927 DOI: 10.1002/hep.28396]

132 **Bajaj JS**, Ahluwalia V, Steinberg JL, Hobgood S, Boling PA, Godschalk M, Habib S, White MB, Fagan A, Gavis EA, Ganapathy D, Hylemon PB, Stewart KE, Keradman R, Liu EJ, Wang J, Gillevet PM, Sikaroodi M, Moeller FG, Wade JB. Elderly patients have an altered gut-brain axis regardless of the presence of cirrhosis. *Sci Rep* 2016; **6**: 38481 [PMID: 27922089 DOI: 10.1038/srep38481]

133 **Akhtar AJ**, Alamy ME, Yoshikawa TT. Extrahepatic conditions and hepatic encephalopathy in elderly patients. *Am J Med Sci* 2002; **324**: 1-4 [PMID: 12120819 DOI: 10.1097/00000441-200207000-00001]

134 **Román E**, Córdoba J, Torrens M, Torras X, Villanueva C, Vargas V, Guarner C, Soriano G. Minimal hepatic encephalopathy is associated with falls. *Am J Gastroenterol* 2011; **106**: 476-482 [PMID: 20978484 DOI: 10.1038/ajg.2010.413]

135 **Vilstrup H**, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD, Weissenborn K, Wong P. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. *Hepatology* 2014; **60**: 715-735 [PMID: 25042402 DOI: 10.1002/hep.27210]

136 **Naveau S**, Giraud V, Ganne N, Perney P, Hastier P, Robin E, Pessione F, Chossegros P, Lahmek P, Fontaine H, Ribard D, Dao T, Filoche B, El Jammal G, Seyrig JA, Dramard JM, Chousterman M, Pillegand B. Patients with alcoholic liver disease hospitalized in gastroenterology. A national multicenter study. *Gastroenterol Clin Biol* 2001; **25**: 131-136 [PMID: 11319436]

137 **Dominguez M**, Rincón D, Abraldes JG, Miquel R, Colmenero J, Bellot P, García-Pagán JC, Fernández R, Moreno M, Bañares R, Arroyo V, Caballería J, Ginès P, Bataller R. A new scoring system for prognostic stratification of patients with alcoholic hepatitis. *Am J Gastroenterol* 2008; **103**: 2747-2756 [PMID: 18721242 DOI: 10.1111/j.1572-0241.2008.02104.x]

138 **Louvet A**, Naveau S, Abdelnour M, Ramond MJ, Diaz E, Fartoux L, Dharancy S, Texier F, Hollebecque A, Serfaty L, Boleslawski E, Deltenre P, Canva V, Pruvot FR, Mathurin P. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. *Hepatology* 2007; **45**: 1348-1354 [PMID: 17518367 DOI: 10.1002/hep.21607]

139 **Thursz MR**, Richardson P, Allison M, Austin A, Bowers M, Day CP, Downs N, Gleeson D, MacGilchrist A, Grant A, Hood S, Masson S, McCune A, Mellor J, O'Grady J, Patch D, Ratcliffe I, Roderick P, Stanton L, Vergis N, Wright M, Ryder S, Forrest EH; STOPAH Trial. Prednisolone or pentoxifylline for alcoholic hepatitis. *N Engl J Med* 2015; **372**: 1619-1628 [PMID: 25901427 DOI: 10.1056/NEJMoa1412278]

140 **Mathurin P**, Moreno C, Samuel D, Dumortier J, Salleron J, Durand F, Castel H, Duhamel A, Pageaux GP, Leroy V, Dharancy S, Louvet A, Boleslawski E, Lucidi V, Gustot T, Francoz C, Letoublon C, Castaing D, Belghiti J, Donckier V, Pruvot FR, Duclos-Vallée JC. Early liver transplantation for severe alcoholic hepatitis. *N Engl J Med* 2011; **365**: 1790-1800 [PMID: 22070476 DOI: 10.1056/NEJMoa1105703]

141 **Rodríquez-Roisin R**, Krowka MJ, Hervé P, Fallon MB; ERS (European Respiratory Society) Task Force-PHD Scientific Committee. Highlights of the ERS Task Force on pulmonary-hepatic vascular disorders (PHD). *J Hepatol* 2005; **42**: 924-927 [PMID: 15973780 DOI: 10.1016/j.jhep.2005.03.002]

142 **Younis I**, Sarwar S, Butt Z, Tanveer S, Qaadir A, Jadoon NA. Clinical characteristics, predictors, and survival among patients with hepatopulmonary syndrome. *Ann Hepatol* 2015; **14**: 354-360 [PMID: 25864216 DOI: 10.1016/S1665-2681(19)31275-X]

143 **Poor H**. Pulmonary Vascular Diseases in the Elderly. *Clin Geriatr Med* 2017; **33**: 553-562 [PMID: 28991650 DOI: 10.1016/j.cger.2017.06.007]

144 **Hoeper MM**, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB. Definitions and diagnosis of pulmonary hypertension. *J Am Coll Cardiol* 2013; **62**: D42-D50 [PMID: 24355641 DOI: 10.1016/j.jacc.2013.10.032]

145 **Ling Y**, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JSR, Howard LS, Pepke-Zaba J, Sheares KKK, Corris PA, Fisher AJ, Lordan JL, Gaine S, Coghlan JG, Wort SJ, Gatzoulis MA, Peacock AJ. Changing Demographics, Epidemiology, and Survival of Incident Pulmonary Arterial Hypertension. *Am J Respir Crit Care Med* 2012;186:790–6[DOI: 10.1164/rccm.201203-0383OC]

146 **Syed MI**, Karsan H, Ferral H, Shaikh A, Waheed U, Akhter T, Gabbard A, Morar K, Tyrrell R. Transjugular intrahepatic porto-systemic shunt in the elderly: Palliation for complications of portal hypertension. *World J Hepatol* 2012; **4**: 35-42 [PMID: 22400084 DOI: 10.4254/wjh.v4.i2.35]

147 **Raevens S**, De Pauw M, Geerts A, Berrevoet F, Rogiers X, Troisi RI, Van Vlierberghe H, Colle I. Prevalence and outcome of diastolic dysfunction in liver transplantation recipients. *Acta Cardiol* 2014; **69**: 273-280 [PMID: 25029872 DOI: 10.2143/AC.69.3.3027830]

148 **Saliba F**, Ichai P, Levesque E, Samuel D. Cirrhotic patients in the ICU: prognostic markers and outcome. *Curr Opin Crit Care* 2013; **19**: 154-160 [PMID: 23426137 DOI: 10.1097/MCC.0b013e32835f0c17]

149 **Chen CY**, Wu CJ, Pan CF, Chen HH, Chen YW. Influence of Age on Critically Ill Patients with Cirrhosis. *Inter J Gerontol* 2015; **9**: 233–238 [DOI: 10.1016/j.ijge.2014.10.003]

150 **Jalan R**, Saliba F, Pavesi M, Amoros A, Moreau R, Ginès P, Levesque E, Durand F, Angeli P, Caraceni P, Hopf C, Alessandria C, Rodriguez E, Solis-Muñoz P, Laleman W, Trebicka J, Zeuzem S, Gustot T, Mookerjee R, Elkrief L, Soriano G, Cordoba J, Morando F, Gerbes A, Agarwal B, Samuel D, Bernardi M, Arroyo V; CANONIC study investigators of the EASL-CLIF Consortium. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. *J Hepatol* 2014; **61**: 1038-1047 [PMID: 24950482 DOI: 10.1016/j.jhep.2014.06.012]

151 **Jalan R**, Pavesi M, Saliba F, Amorós A, Fernandez J, Holland-Fischer P, Sawhney R, Mookerjee R, Caraceni P, Moreau R, Ginès P, Durand F, Angeli P, Alessandria C, Laleman W, Trebicka J, Samuel D, Zeuzem S, Gustot T, Gerbes AL, Wendon J, Bernardi M, Arroyo V; CANONIC Study Investigators; EASL-CLIF Consortium. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. *J Hepatol* 2015; **62**: 831-840 [PMID: 25463539 DOI: 10.1016/j.jhep.2014.11.012]

152 **Tas A**, Akbal E, Beyazit Y, Kocak E. Serum lactate level predict mortality in elderly patients with cirrhosis. *Wien Klin Wochenschr* 2012; **124**: 520-525 [PMID: 22810366 DOI: 10.1007/s00508-012-0208-z]

153 **Wiest R**, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. *Hepatology* 2005; **41**: 422-433 [PMID: 15723320 DOI: 10.1002/hep.20632]

154 **Mancinella A**, Mancinella M, Marigliano B, Marigliano V. Cirrhotic spontaneous bacterial peritonitis in the elderly. *Recenti Prog Med* 2011; **102**: 28-32 [PMID: 21516669]

155 **Terra C**, Guevara M, Torre A, Gilabert R, Fernández J, Martín-Llahí M, Baccaro ME, Navasa M, Bru C, Arroyo V, Rodés J, Ginès P. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. *Gastroenterology* 2005; **129**: 1944-1953 [PMID: 16344063 DOI: 10.1053/j.gastro.2005.09.024]

156 **Fernández J**, Prado V, Trebicka J, Amoros A, Gustot T, Wiest R, Deulofeu C, Garcia E, Acevedo J, Fuhrmann V, Durand F, Sánchez C, Papp M, Caraceni P, Vargas V, Bañares R, Piano S, Janicko M, Albillos A, Alessandria C, Soriano G, Welzel TM, Laleman W, Gerbes A, De Gottardi A, Merli M, Coenraad M, Saliba F, Pavesi M, Jalan R, Ginès P, Angeli P, Arroyo V; European Foundation for the Study of Chronic Liver Failure (EF-Clif). Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. *J Hepatol* 2019; **70**: 398-411 [PMID: 30391380 DOI: 10.1016/j.jhep.2018.10.027]

157 **Friedrich-Rust M**, Wanger B, Heupel F, Filmann N, Brodt R, Kempf VA, Kessel J, Wichelhaus TA, Herrmann E, Zeuzem S, Bojunga J. Influence of antibiotic-regimens on intensive-care unit-mortality and liver-cirrhosis as risk factor. *World J Gastroenterol* 2016; **22**: 4201-4210 [PMID: 27122670 DOI: 10.3748/wjg.v22.i16.4201]

158 **Ramadan HK**, Makhlouf NA, Mahmoud AA, Abd Elrhman M, El-Masry MA. Role of vitamin D deficiency as a risk factor for infections in cirrhotic patients. *Clin Res Hepatol Gastroenterol* 2019; **43**: 51-57 [PMID: 30318356 DOI: 10.1016/j.clinre.2018.09.001]

159 **Anty R**, Anstee QM, Gual P, Tran A. Prophylaxis of bacterial infections in cirrhosis: is an optimal 25-OH vitamin D level required? *J Hepatol* 2014; **61**: 965-966 [PMID: 25020157 DOI: 10.1016/j.jhep.2014.06.039]

160 **Cruz-Jentoft AJ**, Landi F, Schneider SM, Zúñiga C, Arai H, Boirie Y, Chen LK, Fielding RA, Martin FC, Michel JP, Sieber C, Stout JR, Studenski SA, Vellas B, Woo J, Zamboni M, Cederholm T. Prevalence of and interventions for sarcopenia in ageing adults: a systematic review. Report of the International Sarcopenia Initiative (EWGSOP and IWGS). *Age Ageing* 2014; **43**: 748-759 [PMID: 25241753 DOI: 10.1093/ageing/afu115]

161 **European Association for the Study of the Liver**; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. *J Hepatol* 2019; **70**: 172-193 [PMID: 30144956 DOI: 10.1016/j.jhep.2018.06.024]

162 **Parvinian A**, Shah KD, Couture PM, Minocha J, Knuttinen MG, Bui JT, Gaba RC. Older patient age may predict early mortality after transjugular intrahepatic portosystemic shunt creation in individuals at intermediate risk. *J Vasc Interv Radiol* 2013; **24**: 941-946 [PMID: 23707226 DOI: 10.1016/j.jvir.2013.03.018]

163 **Ascha M**, Abuqayyas S, Hanouneh I, Alkukhun L, Sands M, Dweik RA, Tonelli AR. Predictors of mortality after transjugular portosystemic shunt. *World J Hepatol* 2016; **8**: 520-529 [PMID: 27099653 DOI: 10.4254/wjh.v8.i11.520]

164 **Wong F**, Sniderman K, Liu P, Blendis L. The mechanism of the initial natriuresis after transjugular intrahepatic portosystemic shunt. *Gastroenterology* 1997; **112**: 899-907 [PMID: 9041252 DOI: 10.1053/gast.1997.v112.pm9041252]

165 **Su F**, Yu L, Berry K, Liou IW, Landis CS, Rayhill SC, Reyes JD, Ioannou GN. Aging of Liver Transplant Registrants and Recipients: Trends and Impact on Waitlist Outcomes, Post-Transplantation Outcomes, and Transplant-Related Survival Benefit. *Gastroenterology* 2016; **150**: 441-453.e6; quiz e16 [PMID: 26522262 DOI: 10.1053/j.gastro.2015.10.043]

166 **Sharpton SR**, Feng S, Hameed B, Yao F, Lai JC. Combined effects of recipient age and model for end-stage liver disease score on liver transplantation outcomes. *Transplantation* 2014; **98**: 557-562 [PMID: 24717221 DOI: 10.1097/TP.0000000000000090]

167 **Ojo AO**, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. *N Engl J Med* 2003; **349**: 931-940 [PMID: 12954741 DOI: 10.1056/NEJMoa021744]

168 Maurel P, Loustaud-Ratti V, Carrier P, Marie E, Rousseau A, Debette-Gratien M, Silvain C, Causse X, Barbier L, Prémaud A, Salamé E. PS-044 - Effect of longitudinal exposure to tacrolimus on chronic kidney disease occurrence at one year post liver transplantation. *J Hepatol* 2018; **68**: S26 [DOI: 10.1016/S0168-8278(18)30269-1]

169 **Lai JC**, Segev DL, McCulloch CE, Covinsky KE, Dodge JL, Feng S. Physical frailty after liver transplantation. *Am J Transplant* 2018; **18**: 1986-1994 [PMID: 29380529 DOI: 10.1111/ajt.14675]

170 **Feng S**, Goodrich NP, Bragg-Gresham JL, Dykstra DM, Punch JD, DebRoy MA, Greenstein SM, Merion RM. Characteristics associated with liver graft failure: the concept of a donor risk index. *Am J Transplant* 2006; **6**: 783-790 [PMID: 16539636 DOI: 10.1111/j.1600-6143.2006.01242.x]

171 **Gao Q**, Mulvihill MS, Scheuermann U, Davis RP, Yerxa J, Yerokun BA, Hartwig MG, Sudan DL, Knechtle SJ, Barbas AS. Improvement in Liver Transplant Outcomes From Older Donors: A US National Analysis. *Ann Surg* 2018; : [PMID: 29958229 DOI: 10.1097/SLA.0000000000002876]

172 **Aloia TA**, Knight R, Gaber AO, Ghobrial RM, Goss JA. Analysis of liver transplant outcomes for United Network for Organ Sharing recipients 60 years old or older identifies multiple model for end-stage liver disease-independent prognostic factors. *Liver Transpl* 2010; **16**: 950-959 [PMID: 20589647 DOI: 10.1002/lt.22098]

173 **Rana A**, Hardy MA, Halazun KJ, Woodland DC, Ratner LE, Samstein B, Guarrera JV, Brown RS Jr, Emond JC. Survival outcomes following liver transplantation (SOFT) score: a novel method to predict patient survival following liver transplantation. *Am J Transplant* 2008; **8**: 2537-2546 [PMID: 18945283 DOI: 10.1111/j.1600-6143.2008.02400.x]

174 **Dutkowski P**, Oberkofler CE, Slankamenac K, Puhan MA, Schadde E, Müllhaupt B, Geier A, Clavien PA. Are there better guidelines for allocation in liver transplantation? A novel score targeting justice and utility in the model for end-stage liver disease era. *Ann Surg* 2011; **254**: 745-753; discussion 753 [PMID: 22042468 DOI: 10.1097/SLA.0b013e3182365081]

**P-Reviewer:** Kim IH, Manenti A, Yoshioka K **S-Editor:** Cui LJ

**L-Editor:** Filipodia **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** France

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0